NeuBase Therapeutics Management

Management Kriterienprüfungen 1/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Todd Branning

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	2.3yrs
Eigentum des Geschäftsführers	0.04%
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.5yrs

Jüngste Management Updates

Recent updates

We Think NeuBase Therapeutics (NASDAQ:NBSE) Needs To Drive Business Growth Carefully

May 12

Is NeuBase Therapeutics (NASDAQ:NBSE) In A Good Position To Deliver On Growth Plans?

Jan 24

Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

Oct 02

Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

Jun 02

Have Insiders Been Buying NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Shares This Year?

Feb 23

We Think NeuBase Therapeutics (NASDAQ:NBSE) Can Afford To Drive Business Growth

Jan 19

NeuBase Therapeutics EPS in-line

Dec 23

NeuBase Therapeutics reports encouraging data for PATrOL-enabled anti-gene in a type of muscular dystrophy

Dec 16

Do Insiders Own Lots Of Shares In NeuBase Therapeutics, Inc. (NASDAQ:NBSE)?

Dec 15

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Todd Branning im Vergleich zu den Einnahmen von NeuBase Therapeutics verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2023	n/a	n/a	-US$25m
Dec 31 2022	n/a	n/a	-US$30m
Sep 30 2022	US$922k	US$311k	-US$34m

Vergütung im Vergleich zum Markt: Unzureichende Daten, um festzustellen, ob die Gesamtvergütung von Todd im Vergleich zu Unternehmen ähnlicher Größe auf dem Markt US angemessen ist.

Entschädigung vs. Einkommen: Unzureichende Daten, um die Vergütung von Todd mit der Unternehmensleistung zu vergleichen.

Geschäftsführer

Todd Branning (53 yo)

2.3yrs

Amtszeit

US$922,445

Vergütung

Mr. Todd P. Branning serves as an Interim Chief Executive Officer since January 16, 2024 and Chief Financial Officer of NeuBase Therapeutics, Inc. since January 2022 and serves as its Secretary. He joined...

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Dietrich Stephan	Founder	4.8yrs	US$1.15m	6.14% $ 87.1k
Dov Goldstein	Independent Chairperson	4.8yrs	US$74.42k	0.040% $ 567.0
Eric Richman	Independent Director	4.8yrs	US$68.38k	0.060% $ 849.3
George Church	Chairperson of Gene Editing Advisory Board & Member of Scientific Advisory Board	less than a year	keine Daten	keine Daten
Steven Dowdy	Member of Gene Editing & Scientific Advisory Board	4.6yrs	keine Daten	keine Daten
James Coull	Member of Gene Editing Advisory Board	less than a year	keine Daten	keine Daten
Randy Davis	Member of Scientific Advisory Board	3.5yrs	keine Daten	keine Daten
Danith Ly	Member of Advisory Board	no data	keine Daten	keine Daten
Robert Friedlander	Chair of Scientific Advisory Board	no data	keine Daten	keine Daten
Peter Nielsen	Member of Gene Editing & Scientific Advisory Board	3.6yrs	keine Daten	keine Daten
Eriks Rozners	Member of Gene Editing & Scientific Advisory Board	3.5yrs	keine Daten	keine Daten
Gerald Mcdougall	Independent Director	3yrs	US$59.79k	0% $ 0

3.5yrs

Durchschnittliche Betriebszugehörigkeit

56yo

Durchschnittliches Alter

Erfahrener Vorstand: NBSEDie Vorstandsmitglieder gelten als erfahren (3.5 Jahre durchschnittliche Amtszeit).

NeuBase Therapeutics Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Jüngste Management Updates

NeuBase Therapeutics, Inc. Announces CEO Changes

Neubase Therapeutics, Inc. Announces Franklyn G. Prendergast Board of Directors Passed Away

NeuBase Therapeutics, Inc., Annual General Meeting, Sep 28, 2023

High number of new and inexperienced directors

NeuBase Therapeutics, Inc. Announces Resignation of Eric J. Ende as Board of Director

NeuBase Therapeutics, Inc. Announces Formation of Gene Editing Advisory Board

Recent updates

NeuBase Therapeutics, Inc.(NasdaqCM:NBSE) dropped from S&P TMI Index

New major risk - Financial data availability

The Nasdaq Stock Market LLC Notifies NeuBase Therapeutics Regarding Non-Compliance with the Minimum Bid Price Requirement and Ineligible for a Second 180 Calendar Day Period to Regain Compliance

NeuBase Therapeutics, Inc. Announces CEO Changes

New minor risk - Financial data availability

NeuBase Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

Neubase Therapeutics, Inc. Announces Franklyn G. Prendergast Board of Directors Passed Away

New major risk - Shareholder dilution

NeuBase Therapeutics, Inc., Annual General Meeting, Sep 28, 2023

High number of new and inexperienced directors

NeuBase Therapeutics, Inc. announced that it has received $3.512751 million in funding

NeuBase Therapeutics, Inc. Presents Non-Human Primate Data Illustrating Stealth Editors Are Non-Immunogenic, Opening the Door to Redosing

Neubase Therapeutics, Inc. Announces Positive Preclinical Data Supporting the Capabilities of Stealth Editors

NeuBase Therapeutics, Inc. Announces Resignation of Eric J. Ende as Board of Director

NeuBase Therapeutics, Inc. Announces Formation of Gene Editing Advisory Board

Price target decreased to US$10.00

NeuBase Therapeutics, Inc. Announces Resignation of William Mann as President and Chief Operating Officer, Effective October 31, 2022

NeuBase Therapeutics, Inc. to Reduces its Workforce by Approximately 60%

NeuBase Therapeutics, Inc. Announces Executive Changes

Price target decreased to US$10.67

NeuBase Therapeutics Receives Non-Compliance Letter from Nasdaq

Can NeuBase Therapeutics (NASDAQ:NBSE) Afford To Invest In Growth?

NeuBase Therapeutics GAAP EPS of -$0.26 beats by $0.04

NeuBase Therapeutics, Inc., Annual General Meeting, Sep 08, 2022

NeuBase Therapeutics, Inc. Announces Promotion of William Mann to President

NeuBase Therapeutics promotes Dr. William Mann to President and COO

NeuBase Therapeutics, Inc. Presents New Preclinical Data At ASGCT 2022 for Its Dm1 Program Demonstrating Wide Tissue Distribution and Supporting Differentiated Whole-Body Treatment Solution

We Think NeuBase Therapeutics (NASDAQ:NBSE) Needs To Drive Business Growth Carefully

Price target decreased to US$14.67

High number of new and inexperienced directors

Price target decreased to US$14.67

Price target decreased to US$15.50

Is NeuBase Therapeutics (NASDAQ:NBSE) In A Good Position To Deliver On Growth Plans?

CFO, Treasurer & Secretary Samuel Backenroth has left the company

Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

NeuBase Therapeutics, Inc.(NasdaqCM:NBSE) dropped from Russell 3000E Index

NeuBase Therapeutics Demonstrates Functional Rescue in Myotonic Dystrophy Type 1 Model and Allele-Selective Inhibition of KRAS Mutations to Inhibit Tumor Growth

Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

Independent Director has left the company

Have Insiders Been Buying NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Shares This Year?

Price target raised to US$17.00

New 90-day high: US$11.66

New 90-day high: US$10.08

We Think NeuBase Therapeutics (NASDAQ:NBSE) Can Afford To Drive Business Growth

New 90-day low: US$7.27

NeuBase Therapeutics EPS in-line

NeuBase Therapeutics Announces Positive Preclinical in Vivo Data for Patrol Enabled Anti-Gene for the Treatment of Myotonic Dystrophy Type 1

NeuBase Therapeutics reports encouraging data for PATrOL-enabled anti-gene in a type of muscular dystrophy

Do Insiders Own Lots Of Shares In NeuBase Therapeutics, Inc. (NASDAQ:NBSE)?

NeuBase Therapeutics Announces Appointment of Curt Bradshaw as Chief Scientific Officer

NeuBase Therapeutics Announces Addition of Eriks Rozners and Randy Davis to Scientific Advisory Board

NeuBase Therapeutics, Inc. Announces Addition of Peter Nielsen, Ph.D., Inventor of Peptide Nucleic Acid Technology, to Scientific Advisory Board

NeuBase Therapeutics, Inc. Enters into Lease Agreement with 350 Technology Drive Partners, LLC

New 90-day low - US$7.46

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter